Citadel Advisors
CINC

Citadel Advisors’s CinCor Pharma, Inc. Common Stock CINC Stock Holding History

Citadel Advisors’s Portfolio CINC Stock Details CINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,800
Closed -$95.9K – 16102
2022
Q4 		$95.9K Buy
+7,800
New +$186K ﹤0.01% 11280

Citadel Advisors's CINC Position: Q1 2023 in Review

Citadel Advisors sold out of CinCor Pharma, Inc. Common Stock (CINC) in Q1 2023, closing a stake of 197,896 shares — an estimated $2.43M sold.

Citadel Advisors first reported a position in CINC in Q3 2022 and held it in 2 quarters. The position peaked at $2.43M in Q4 2022. 0 funds tracked by Wall St. Rank hold CINC as of Q1 2023.

  • Citadel Advisors reported no remaining CinCor Pharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 197,896 CinCor Pharma, Inc. Common Stock shares in Q1 2023, an estimated $2.43M.
  • Citadel Advisors first reported a position in CinCor Pharma, Inc. Common Stock in Q3 2022 and held it in 2 quarters.
  • Citadel Advisors's CinCor Pharma, Inc. Common Stock position peaked at $2.43M in Q4 2022.
  • 0 funds tracked by Wall St. Rank held CinCor Pharma, Inc. Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.